TA146 Adalimumab ar gyfer soriasis: deall canllawiau NICE (fformat MS Word)
History
A list of downloadable documents created during development.
Other information
Background information
-
-
Appendix A: Decision paper presented to the Institute's Guidance Executive
-
Appendix A: Decision paper presented to the Institute's Guidance Executive (PDF 105 KB)
-
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 285 KB)
-
NICE issues guidance on the use of adalimumab for the treatment of psoriasis in adults (PDF 29 KB)
-
-
-
Provisional matrix of consultees and commentators (MSWord 67 KB)
-
-
Summary of the responses from this consultation
-
Review decision - December 2008: table of comments (PDF 43 KB)
Psoriasis - adalimumab: final appraisal determination (FAD)
-
Psoriasis - adalimumab: final appraisal determination (FAD) information
-
Psoriasis - adalimumab: final appraisal determination (FAD)
-
Psoriasis - adalimumab: final appraisal determination (FAD) (PDF 112 KB)
-
Response to consultee, commentator and public comments on the ACD and comments from website consultation
-
-
Consultee and commentator comments on the ACD
-
Wyeth Pharmaceuticals
-
-
Welsh Assembly Government
-
-
Royal College of Nursing
-
-
Merck Serono
-
-
Department of Health
-
-
British Association of Dermatologists
-
-
Abbott Laboratories
-
Psoriasis - adlimumab: appraisal consultation
-
-
Psoriasis - adalimumab: appraisal consultation document information
-
Psoriasis - adalimumab: appraisal consultation - pre-meeting briefing
-
Psoriasis - adalimumab: appraisal consultation - pre-meeting briefing (PDF 179 KB)
-
Psoriasis - adalimumab: appraisal consultation - Evidence Review Group report
-
Psoriasis - adalimumab: appraisal consultation - Evidence Review Group report (PDF 448 KB)
-
Psoriasis - adalimumab: appraisal consultation - Non-manufacturer submissions
-
British Association of Dermatologists
-
-
Psoriasis and Psoriatic Arthritis Alliance
-
-
Psoriasis Association
-
-
Royal College of Nursing
-
-
Royal College of Physicians
-
-
Welsh Assembly Government
-
-
Psoriasis - adalimumab: appraisal consultation - Manufacturer submission: Abbott Laboratories Ltd
-
-
Psoriasis - adalimumab: appraisal consultation - Expert written personal statements
-
Barker
-
-
Chandler
-
-
Griffiths
-
-
Jobling
-
Psoriasis - adalimumab: Draft scope - pre-referral
-
Psoriasis - adalimumab: Draft scope - pre-referral
-
Psoriasis - adalimumab: Draft scope - pre-referral (PDF 32 KB)
Psoriasis - adalimumab: Provisional matrix of consultees and commentators - pre- referral
-
Psoriasis - adalimumab: Provisional matrix of consultees and commentators - pre- referral
-
Psoriasis - adalimumab: Response to comments on the draft scope
-
Psoriasis - adalimumab: Response to comments on the draft scope
-
Psoriasis - adalimumab: Response to comments on the draft scope (PDF 126 KB)